Elise F. Nassif, M.D., M.S.

Peer-Reviewed Articles

1. Nassif EF, Keung EZ, Thirasastr P, Somaiah N. Myxoid Liposarcomas: Systemic Treatment Options. Curr Treat Options Oncol 24(4):274-291, 2023. e-Pub 2023. PMID: 36853469.
2. Cope BM, Traweek RS, Lazcano R, Keung EZ, Lazar AJ, Roland CL, Nassif EF. Targeting the Molecular and Immunologic Features of Leiomyosarcoma. Cancers (Basel) 15(7), 2023. e-Pub 2023. PMID: 37046760.
3. Thirasastr P, Lin H, Amini B, Wang WL, Cloutier JM, Nassif EF, Keung EZ, Roland CL, Feig B, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Zhou X, Somaiah N. Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma. Cancer Med 12(4):4282-4293, 2023. e-Pub 2022. PMID: 36151848.
4. Erstad DJ, Chiang YJ, Witt RG, Cope B, Nassif EF, Scally CP, Torres KE, Feig BW, Hunt KK, Bishop AJ, Guadagnolo BA, Roland CL, Keung EZ. Clinical Impact of External Beam Radiotherapy for Surgically Resected Primary Retroperitoneal Liposarcoma. Ann Surg Oncol 30(2):926-940, 2023. e-Pub 2022. PMID: 36115928.
5. Erstad DJ, Chiang YJ, Witt RG, Cope B, Nassif EF, Scally CP, Torres KE, Feig BW, Hunt KK, Bishop AJ, Guadagnolo BA, Roland CL, Keung EZ. ASO Visual Abstract: Clinical Impact of External Beam Radiotherapy for Surgically Resected Primary Retroperitoneal Liposarcoma. Ann Surg Oncol 30(2):941-942, 2023. PMID: 36161369.
6. Nassif EF, Joseph CP, Lazcano R, Joseph JT, Thirasastr P, Lazar AJ, Somaiah N. Case report: Responses to the combination of gemcitabine with sirolimus in two patients with TSC-mutated sarcomas. Front Oncol 13:1046442, 2023. e-Pub 2023. PMID: 36845725.
7. Torregrosa C, Pernot S, Vaflard P, Perret A, Tournigand C, Randrian V, Doat S, Neuzillet C, Moulin V, Stouvenot M, Roth G, Darbas T, Auberger B, Godet T, Jaffrelot M, Lambert A, Dubreuil O, Gluszak C, Bernard-Tessier A, Turpin A, Palmieri LJ, Bouche O, Goujon G, Lecomte T, Sefrioui D, Locher C, Grados L, Gignoux P, Trager S, Nassif E, Saint A, Hammel P, Lecaille C, Bureau M, Perrier M, Botsen D, Bourgeois V, Taieb J, Auclin E. FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study. Int J Cancer 151(11):1978-1988, 2022. e-Pub 2022. PMID: 35833561.
8. Witt RG, Cope B, Erstad DJ, Chiang YJ, Nassif EF, Scally CP, Torres KE, Hunt KK, Feig BW, Roland CL, Keung EZ. Sentinel Lymph Node Biopsy and Formal Lymphadenectomy for Soft Tissue Sarcoma: A Single Center Experience of 86 Consecutive Cases. Ann Surg Oncol 29(11):7092-7100, 2022. e-Pub 2022. PMID: 35501583.
9. Somaiah N, Conley AP, Parra ER, Lin H, Amini B, Solis Soto L, Salazar R, Barreto C, Chen H, Gite S, Haymaker C, Nassif EF, Bernatchez C, Mitra A, Livingston JA, Ravi V, Araujo DM, Benjamin R, Patel S, Zarzour MA, Sabir S, Lazar AJ, Wang WL, Daw NC, Zhou X, Roland CL, Cooper ZA, Rodriguez-Canales J, Futreal A, Soria JC, Wistuba II, Hwu P. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol 23(9):1156-1166, 2022. e-Pub 2022. PMID: 35934010.
10. Nassif EF, Cope B, Traweek R, Witt RG, Erstad DJ, Scally CP, Thirasastr P, Zarzour MA, Ludwig J, Benjamin R, Bishop AJ, Guadagnolo BA, Ingram D, Wani K, Wang WL, Lazar AJ, Torres KE, Hunt KK, Feig BW, Roland CL, Somaiah N, Keung EZ. Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. Int J Cancer 150(12):2012-2024, 2022. e-Pub 2022. PMID: 35128664.
11. Nassif EF, Blay JY, Massard C, Dufresne A, Brahmi M, Cassier P, Ray-Coquard I, Pautier P, Leary A, Sunyach MP, Bahleda R, Levy A, Le Pechoux C, Honoré C, Mir O, Le Cesne A. Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials. ESMO Open 7(2):100425, 2022. e-Pub 2022. PMID: 35255445.
12. Lazcano R, Barreto CM, Salazar R, Carapeto F, Traweek RS, Leung CH, Gite S, Mehta J, Ingram DR, Wani KM, Vu KT, Parra ER, Lu W, Zhou J, Witt RG, Cope B, Thirasastr P, Lin HY, Scally CP, Conley AP, Ratan R, Livingston JA, Zarzour AM, Ludwig J, Araujo D, Ravi V, Patel S, Benjamin R, Wargo J, Wistuba II, Somaiah N, Roland CL, Keung EZ, Solis L, Wang WL, Lazar AJ, Nassif EF. The immune landscape of undifferentiated pleomorphic sarcoma. Front Oncol 12:1008484, 2022. e-Pub 2022. PMID: 36313661.
13. Traweek RS, Cope BM, Roland CL, Keung EZ, Nassif EF, Erstad DJ. Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma. Front Oncol 12:1006959, 2022. e-Pub 2022. PMID: 36439412.
14. Nassif EF, Auclin E, Bahleda R, Honoré C, Mir O, Dumont S, Mery B, Hodroj K, Brahmi M, Trédan O, Ray-Coquard I, Blay JY, Massard C, Le Cesne A, Dufresne A. TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials. Cancers (Basel) 13(13), 2021. e-Pub 2021. PMID: 34282771.
15. Nassif EF, Maloney N, Conley AP, Keung EZ. Disseminated Coccidioidomycosis Following COVID-19 Mimicking Metastatic Thoracic Relapse of Well-Differentiated Liposarcoma: A Case Report. Front Med (Lausanne) 8:715939, 2021. e-Pub 2021. PMID: 34589500.
16. Roulleaux Dugage M*, Nassif EF*, Italiano A, Bahleda R. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review. Front Immunol 12:775761, 2021. e-Pub 2021. PMID: 34925348.
17. Nassif EF, Mlecnik B, Thibault C, Auvray M, Bruni D, Colau A, Compérat E, Bindea G, Catteau A, Fugon A, Boquet I, Martel M, Camparo P, Colin P, Zakopoulou R, Bamias A, Bennamoun M, Barthere X, D'acremont B, Lefevre M, Audenet F, Mejean A, Verkarre V, Oudard S, Galon J. The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival. Cancers (Basel) 13(3), 2021. e-Pub 2021. PMID: 33525361.
18. Boilève A, Dufresne A, Chamseddine A, Nassif E, Dumont S, Brahmi M, Adam J, Rouleau E, Karanian M, Haddad V, Faron M, Honoré C, Meeus P, Le Cesne A, Blay JY, Mir O. Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment. ESMO Open 5(6):e001082, 2020. PMID: 33246932.
19. Honoré C, Delhorme JB, Nassif E, Faron M, Ferron G, Bompas E, Glehen O, Italiano A, Bertucci F, Orbach D, Pocard M, Quenet F, Blay JY, Carrere S, Chevreau C, Mir O, Le Cesne A, French Network for Rare Peritoneal Malignancies (RENAPE), French Sarcoma Clinical Network (NETSARC). Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patients. Surg Oncol 29:107-112, 2019. e-Pub 2019. PMID: 31196472.
20. Nassif EF, Arsène-Henry A, Kirova YM. Brain metastases and treatment: multiplying cognitive toxicities. Expert Rev Anticancer Ther 19(4):327-341, 2019. e-Pub 2019. PMID: 30755047.
21. Nassif E, Thibault C, Vano Y, Fournier L, Mauge L, Verkarre V, Timsit MO, Mejean A, Tartour E, Oudard S. Sunitinib in kidney cancer: 10 years of experience and development. Expert Rev Anticancer Ther 17(2):129-142, 2017. e-Pub 2016. PMID: 27967249.

Invited Articles

1. Gingrich AA, Nassif EF, Roland CL, Keung EZ. The Landscape of Immunotherapy for Retroperitoneal Sarcoma. Curr Oncol 30(2):2144-2158, 2023. e-Pub 2023. PMID: 36826126.
2. Nassif EF, Thibault C, Oudard S, Galon J. Precision immunity: Immunoscore and neoadjuvant treatment in bladder cancer. Oncoimmunology 10(1):1888488, 2021. e-Pub 2021. PMID: 33659099.

Abstracts

1. Traweek RS, Lazcano R, Cope BM, Bishop AJ, Guadagnolo BA, Ingram DR, Wani K, Lazar AJ, Wang WL, Scally CP, Keung EZ, Torres KE, Hunt KK, Nassif EF, Roland CL. Major Pathologic Response (MPR) Following Neoadjuvant Radiation Therapy (RT) +/- immune-checkpoint Blockade (ICB) Is Associated with Improved Survival in Undifferentiated Pleomorphic Sarcoma (UPS). American Radium Society Annual Meeting, 2023.
2. Traweek RS, Witt RG, Snyder RA, Nassif E, Lyu H, Krijgh DD, Smith JM, Tilney GS, Fen C, Torres KE, Roubaud ME, Scally CP, Hunt KK, Feig BW, Keung EZ, Mericli AF, Roland CL. Social vulnerability is associated with worse survival among patients with extremity and truncal soft-tissue sarcoma. Society of Surgical Oncology Annual Meeting, 2023.
3. Nassif EF, Liu B, Wang WL, Lazar AJ, Ingram D, Wani K, Duncan S, Tate T, Mathew G, Crosby S, Shaw K, Zelazowska M, Feig BW, Torres KE, Hunt KK, Guadagnolo BA, Bishop AJ, Futreal A, Wargo JA, Somaiah N, McBride K, Roland CL, Keung EZ. B-Cell Receptor (BCR) Repertoire is a Dynamic Biomarker of Survival in Sarcoma Patients Treated with Neoadjuvant Immune Checkpoint Blockade (ICB). SITC Annual Meeting, 2022.
4. Chelvanambi M, Deboever N, Nassif EF, Damania AV, Chen L, Leung CH, Wu CC, Keung EZ, Witt RG, White MG, Johnson SB, Wong MC, Mishra AK, Lastrapes MJ, Somaiah N, Kadara H, Basu S, Allison JP, Sharma P, McBride KM, Fridman WH, Heymach J, Sepesi B, Ajami NJ, Roland CL, Wargo JA, Cascone T. Metagenomic sequencing reveals unique gut microbial features associated with tertiary lymphoid structures in response to immune checkpoint blockade in solid cancers. SITC Annual Meeting, 2022.
5. Traweek, RS, Witt RG, Nassif EF, Ajami NJ, Mishra AK, Damania AV, Chelvanambi M, Wang WL, Lazar AJ, Keung EZ, Torres KE, Scally CP, Zhang X, Daniel-MacDougall CR, Wargo JA, Somaiah N, Roland CL. Dietary fiber intake is associated with increased tertiary lymphoid structures in dedifferentiated liposarcoma following immune checkpoint blockade. SITC Annual Meeting, 2022.
6. Genestie C, Giudici F, Leary A, Scoazec JY, Nassif E, Pautier P. Immune Infiltration As Prognostic Factors in Metastatic Leiomyosarcoma. CTOS Annual Meeting, 2022.
7. Nassif EF, Keung EZ, Jiang P, Reuben A, Crosby S, Mathew G, Lazar AJ, Torres KE, Wang WL, Guadagnolo BA, Bishop AJ, Hunt KK, Bird JE, Lewis VO, Conley AP, Wargo JA, Somaiah N, Roland CL. Peripheral Immune Biomarkers of Survival in Patients with Resectable Dedifferentiated Liposarcomas (DDLPS) and Undifferentiated Pleomorphic Sarcomas (UPS) Treated with Neoadjuvant Nivolumab +/- Ipilimumab (neoICB). ESMO Annual Meeting, 2022.
8. Nassif EF, Chelvanambi M, Chen L, Wu CC, Damania A, Keung EZ, Witt R, White MG, Ajami NJ, Wong MC, Somaiah N, Sepesi B, Basu S, Allison JP, Sharma P, McBride K, Fridman WH, Wargo JA, Cascone T, Roland CL. Identifying gut microbial signatures associated with B-cells and tertiary lymphoid structures (TLS) in the tumor microenvironment (TME) in response to immune checkpoint blockade (ICB). ASCO Annual Meeting, 2022.
9. Keung EZ, Nassif EF, Lin HY, Lazar AJ, Torres KE, Wang WL, Guadagnolo AB, Bishop AJ, Hunt KK, Feig BW, Bird JE, Lewis VO, Ratan R, Patel S, McBride K, Liu B, Zelazowska M, Wargo JA, Roland CL, Somaiah N. Randomized phase II study of neoadjuvant immune checkpoint blockade (ICB) for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS): survival results after 2 years of follow-up and intratumoral B-Cell Receptor (BCR) correlates. ASCO Annual Meeting, 2022.
10. Nassif EF, Wu CC, Akdemir K, Witt RG, Traweek R, Cope B, Thirasastr P, Tate T, Mathew G, Crosby S, Chu R, Mohammad M, Shaw K, Ingram D, Wani K, Lazar AJ, Wang WL, Duncan S, Guadagnolo BA, Bishop AJ, Lewis V, Bird JE, Torres KE, Hunt KK, Feig BW, Scally CP, Ratan R, Patel S, Benjamin R, Satcher R, McBride K, Fridman WH, Wistuba I, Futreal A, Wargo JA, Somaiah N, Roland CL, Keung EZ. Antigen presentation and processing pathway is associated with early relapse after neoadjuvant immune checkpoint blockade (ICB) in dedifferentiated liposarcomas (DDLPS). AACR special conference on sarcoma, 2022.
11. Nassif EF, Le Cesne A, Massard C, Mezquita L, Roulleaux-Dugage M, Bahleda R, Dufresne A, Brahmi M, Ray-Coquard I, Pautier P, Leary A, Levy A, Le Pechoux C, Honore C, Mir O, Besse B, Blay JY, Auclin E. Association of Lung Immune Prognostic Index (LIPI) with Progression-free survival (PFS) in soft-tissue sarcoma (STS) patients treated with immunotherapy (IO) in early phase trials. ESMO Immuno-Oncology Annual Meeting, 2021.
12. Traweek R, Keung EZ, Ajami NJ, Duncan S, Burton E, Tate T, Callahan K, Ingram D, Wani K, Lazar AJ, Wang WL, Guadagnolo BA, Bishop AJ, Wargo JA, Somaiah N, Roland CL, Nassif EF. Fecal microbiome in soft-tissue sarcoma (STS) patients treated with neoadjuvant immune checkpoint blockade (ICB). ESMO Immuno-Oncology Annual Meeting, 2021.
13. Nassif EF, Roland CL, Thirasastr P, Scally CP, Zarzour A, Valenzuela R, Torres KE, Hunt KK, Feig BW, Wang WL, Lazar AJ, Somaiah N, Keung EZ. Surgical outcomes of patients with well-differentiated and dedifferentiated retroperitoneal liposarcomas treated with palbociclib. CTOS Annual Meeting, 2021.
14. Thirasastr P, Amini B, Lin H, Roland C, Keung EZ, Nassif E, Araujo D, Benjamin RS, Conley AP, Gorlick R, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour A, Zhou X, Somaiah N. Efficacy of gemcitabine-docetaxel in dedifferentiated liposarcoma. CTOS Annual Meeting, 2021.
15. Keung EZ, Nassif EF, Lin H, Lazar AJ, Wang WL, Parra ER, Lima CF, Wistuba I, Guadagnolo BA, Bishop AJ, Lewis V, Torres KE, Hunt KK, Feig BW, Scally CP, Al Rawi AN, Crosby S, Mathew G, Ingram D, Wani K, Wargo JA, Somaiah N, Roland CL. Immune infiltrates are associated with clinical outcomes in patients with resectable soft tissue sarcoma treated with neoadjuvant immune checkpoint blockade. SITC Annual Meeting, 2021.
16. Nassif EF, Auclin E, Bahleda R, Honoré C, Mir O, Dumont S, Mery B, Hodroj K, Brahmi M, Trédan O, Ray-Coquard I, Blay JY, Massard C, Le Cesne A, Dufresne A, Le Pechoux C, Levy A, Komaki R. Impact of peri-operative radiotherapy on localized sarcomas with TP53 alterations: retrospective pooled analysis of two precision medicine trials. American Radium Society Annual Meeting, 2021.
17. Nassif EF, Bahleda R, Auclin E, Honoré C, Dumont S, Brahmi M, Tredan O, Mir O, Ray-Coquard I, Le Cesne A, Blay JY, Massard C, Dufresne A. TP53 as a prognostic marker in patients with advanced sarcoma: a pooled analysis of MOSCATO and ProilER studies. CTOS Annual Meeting, 2020.
18. Nassif EF, Mlecnik B, Thibault C, Barthere X, Auvray M, Bruni D, Comperat E, Colau A, Hermitte F, Camparo P, Colin P, Bruno D, Bennamoun M, Audenet F, Mejean A, Verkarre V, Zakopoulou R, Bamias A, Oudard S, Galon J. The Immunoscore in patients with urothelial carcinoma treated with neoadjuvant chemotherapy: clinical significance for pathological response and survival. ESMO Annual Meeting, 2019.
19. Assi TS, Le Cesne A, Nassif E, Cavalcanti A, Faron M, Ibrahim T, Le Pechoux C, Mir O, Adam J, Dumont S, Terrier P, Honore C. Adriamycin and ifosfamide-based regimen as induction chemotherapy in desmoplastic small round cell tumors: Results of a retrospective single-center study on 34 patients. ESMO Annual Meeting, 2018.
20. Delhorme JB, Nassif E, Ferron G, Bompas E, Adam J, Glehen O, Italiano A, Bertucci F, Orbach D, Le Cesne A, Blay JY, Chevreau CM, Mir O, Honoré C. Can we cure patients with abdominal desmoplastic small round cell tumor? Results of a retrospective multicentric study on 100 patient. ESMO Annual Meeting, 2018.
21. Nassif E, De Forceville L, Geraud A, Gantzer J, Honoré C, Dumont SN, Mir O, De Baere T, Blay JY, Le Cesne A. Retrospective study of complete remission imatinib-free metastatic gastro-intestinal stromal tumors (GIST). ASCO Annual Meeting, 2018.

Letters to the Editor

1. Nassif EF, Roland CL, Keung EZ. Reflections on the value of multidisciplinary oncology training by a medical oncologist. Eur J Surg Oncol.